CTI BioPharma Corp.
CTIC · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.4% | 15.6% | 48% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.9% | 94.5% | 93.7% | 92.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -32.5% | -65% | -61.7% | -146.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -90.4% | -80.3% | -85.7% | -183.8% |
| EPS Diluted | -0.17 | -0.13 | -0.13 | -0.21 |
| % Growth | -30.8% | 0% | 38.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |